269 related articles for article (PubMed ID: 29467321)
1. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Moschos SJ; Sullivan RJ; Hwu WJ; Ramanathan RK; Adjei AA; Fong PC; Shapira-Frommer R; Tawbi HA; Rubino J; Rush TS; Zhang D; Miselis NR; Samatar AA; Chun P; Rubin EH; Schiller J; Long BJ; Dayananth P; Carr D; Kirschmeier P; Bishop WR; Deng Y; Cooper A; Shipps GW; Moreno BH; Robert L; Ribas A; Flaherty KT
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467321
[TBL] [Abstract][Full Text] [Related]
2. A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Varga A; Soria JC; Hollebecque A; LoRusso P; Bendell J; Huang SA; Wagle MC; Okrah K; Liu L; Murray E; Sanabria-Bohorquez SM; Tagen M; Dokainish H; Mueller L; Burris H
Clin Cancer Res; 2020 Mar; 26(6):1229-1236. PubMed ID: 31848189
[TBL] [Abstract][Full Text] [Related]
3. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson D; Griffin MJ; Sludden J; Drew Y; Cresti N; Swales K; Merriman M; Allen R; Bevan P; Buerkle M; Mala C; Coyle V; Rodgers L; Dean E; Greystoke A; Banerji U; Wilson RH; Evans TR; Anthoney A; Ranson M; Boddy AV; Plummer R
Eur J Cancer; 2016 Nov; 68():1-10. PubMed ID: 27693888
[TBL] [Abstract][Full Text] [Related]
4. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Sullivan RJ; Infante JR; Janku F; Wong DJL; Sosman JA; Keedy V; Patel MR; Shapiro GI; Mier JW; Tolcher AW; Wang-Gillam A; Sznol M; Flaherty K; Buchbinder E; Carvajal RD; Varghese AM; Lacouture ME; Ribas A; Patel SP; DeCrescenzo GA; Emery CM; Groover AL; Saha S; Varterasian M; Welsch DJ; Hyman DM; Li BT
Cancer Discov; 2018 Feb; 8(2):184-195. PubMed ID: 29247021
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Weekes CD; Von Hoff DD; Adjei AA; Leffingwell DP; Eckhardt SG; Gore L; Lewis KD; Weiss GJ; Ramanathan RK; Dy GK; Ma WW; Sheedy B; Iverson C; Miner JN; Shen Z; Yeh LT; Dubowy RL; Jeffers M; Rajagopalan P; Clendeninn NJ
Clin Cancer Res; 2013 Mar; 19(5):1232-43. PubMed ID: 23434733
[TBL] [Abstract][Full Text] [Related]
6. Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Stathis A; Tolcher AW; Wang JS; Renouf DJ; Chen LC; Suttner LH; Freshwater T; Webber AL; Nayak T; Siu LL
Invest New Drugs; 2023 Jun; 41(3):380-390. PubMed ID: 37040046
[TBL] [Abstract][Full Text] [Related]
7. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG
Invest New Drugs; 2018 Oct; 36(5):886-894. PubMed ID: 29766337
[TBL] [Abstract][Full Text] [Related]
10. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
11. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Sarker D; Ang JE; Baird R; Kristeleit R; Shah K; Moreno V; Clarke PA; Raynaud FI; Levy G; Ware JA; Mazina K; Lin R; Wu J; Fredrickson J; Spoerke JM; Lackner MR; Yan Y; Friedman LS; Kaye SB; Derynck MK; Workman P; de Bono JS
Clin Cancer Res; 2015 Jan; 21(1):77-86. PubMed ID: 25370471
[TBL] [Abstract][Full Text] [Related]
12. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
13. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
Rosen LS; LoRusso P; Ma WW; Goldman JW; Weise A; Colevas AD; Adjei A; Yazji S; Shen A; Johnston S; Hsieh HJ; Chan IT; Sikic BI
Invest New Drugs; 2016 Oct; 34(5):604-13. PubMed ID: 27424159
[TBL] [Abstract][Full Text] [Related]
14. Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.
Harding JJ; Bauer TM; Tan DSW; Bedard PL; Rodon J; Doi T; Schnell C; Iyer V; Baffert F; Radhakrishnan R; Fabre C; Juric D
Invest New Drugs; 2019 Apr; 37(2):271-281. PubMed ID: 30073466
[TBL] [Abstract][Full Text] [Related]
15. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD
Breast Cancer Res; 2018 Aug; 20(1):82. PubMed ID: 30071865
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Leong S; Moss RA; Bowles DW; Ware JA; Zhou J; Spoerke JM; Lackner MR; Shankar G; Schutzman JL; van der Noll R; Voest EE; Schellens JHM
Oncologist; 2017 Dec; 22(12):1491-1499. PubMed ID: 28798270
[TBL] [Abstract][Full Text] [Related]
17. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.
Cohen RB; Aamdal S; Nyakas M; Cavallin M; Green D; Learoyd M; Smith I; Kurzrock R
Eur J Cancer; 2013 May; 49(7):1521-9. PubMed ID: 23433846
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
20. Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models.
Kopczynski M; Rumienczyk I; Kulecka M; Statkiewicz M; Pysniak K; Sandowska-Markiewicz Z; Wojcik-Trechcinska U; Goryca K; Pyziak K; Majewska E; Masiejczyk M; Wojcik-Jaszczynska K; Rzymski T; Bomsztyk K; Ostrowski J; Mikula M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]